Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Jagsonpal Pharmaceuticals FCF Yield % Related Terms
Jagsonpal Pharmaceuticals FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jagsonpal Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jagsonpal Pharmaceuticals FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jagsonpal Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Jagsonpal Pharmaceuticals's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jagsonpal Pharmaceuticals (BOM:507789) has a FCF Yield % of 3.08 as of Jul. 13, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Jagsonpal Pharmaceuticals and its competitors. According to the industry distribution chart, Jagsonpal Pharmaceuticals ranks #350 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 34.8%.
Is Jagsonpal Pharmaceuticals' FCF Yield % too high?
Jagsonpal Pharmaceuticals' current FCF Yield % is 3.08. The Drug Manufacturers industry median FCF Yield % is 0.67. Jagsonpal Pharmaceuticals' value of 3.08 is 359.7% above this industry median. Based on the distribution chart, Jagsonpal Pharmaceuticals ranks #350 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jagsonpal Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jagsonpal Pharmaceuticals' FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jagsonpal Pharmaceuticals ranks #350 out of 1006 companies for FCF Yield %. This puts Jagsonpal Pharmaceuticals in the upper half of its industry. The industry median FCF Yield % is 0.67. Jagsonpal Pharmaceuticals' value of 3.08 is 359.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jagsonpal Pharmaceuticals's current FCF Yield % of 3.08 is 359.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Jagsonpal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jagsonpal Pharmaceuticals's current FCF Yield % is 3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jagsonpal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals (BOM:507789) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹205.36, compared to a current price of ₹230.00 — trading 12% above its estimated fair value. The current FCF Yield % is 3.08 and 359.7% above the Drug Manufacturers industry median of 0.67. Jagsonpal Pharmaceuticals' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Jagsonpal Pharmaceuticals (BOM:507789), the current FCF Yield % is 3.08 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jagsonpal Pharmaceuticals (BOM:507789) Overvalued in 2026?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹230.00 is trading 12% above its estimated GF Value™ of ₹205.36.
GuruFocus considers Jagsonpal Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for BOM:507789:
FCF Yield %: 3.08
GF Value™: ₹205.36 vs. price of ₹230.00 (12% above fair value)
Industry Position: 359.7% above the Drug Manufacturers median (#350 of 1006)
No single metric tells the full story. See the BOM:507789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others.
73GF Score
Get the complete analysis for BOM:507789
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507789 has been successfully added to your 
